Increased sugar consumption has been proposed to be a risk factor for obesity-related metabolic disorders. The objective of this study was to investigate the anti-inflammatory effect of turanose in Raw 264.7 macrophages. Turanose (3-O--D-glucosyl-D-fructose), an isomer of sucrose, naturally exists in honey. For these studies, macrophages were treated with total glucose (Glu), 50% Glu/50% turanose (T50), 25% Glu/75% turanose (T75), and 100% turanose (T100), each with a total concentration of 25 mM in cell media. Expressions of inflammatory enzymes and cytokines were analyzed. Cell viability was not affected in the turanose treated groups compared to the Glu group. Lipopolysaccharide and glucose-induced nitric oxide production, protein expression of inducible nitric oxide synthase, COX-2, and superoxide dismutase 2, and mRNA expression levels of interleukin (IL)-1 and IL-18 were significantly suppressed by turanose treatment. These results demonstrate that turanose exerts anti-inflammatory effects in vitro, and possesses potential to serve therapeutic functional sweetener for testing in vivo and in clinical trials. 
INTRODUCTION
Sucrose is a disaccharide that is composed of glucose and fructose. Sucrose is used for a variety of applications, especially in the food industry where it is used as a sweetener and as a standard for sweetness. However, excessive intake of sucrose can increase an individual's susceptibility to chronic diseases, including tooth decay, obesity, and type 2 diabetes. 1 Sucrose is rapidly hydrolyzed into glucose and fructose in human intestines and increases the blood glucose level. A well-controlled blood glucose level is thought to be beneficial for treating excessive inflammatory responses and related metabolic diseases. Inflammation is related to the pathogenesis of many diseases, including cardiovascular disease, arthritis, and atherosclerosis. 2, 3 Inflammation is initiated by bacterial infections and extrinsic toxic chemicals, and results in the injury and death of normal cells. Tissue injury induced by these factors leads to the release of inflammatory mediators, including interleukin (IL)-18, IL-1, and nitric oxide (NO), from macrophages, monocytes, and leukocytes. 4 Macrophages recognize pathogenic substances via cell surface receptors and initiate inflammatory responses by secreting various pro-inflammatory mediators. 5 Lipopolysaccharide (LPS) is a well characterized stimulant for macrophage and induces the production of inflammatory mediators, such as NO and immune cytokines, including IL-1 and IL-18. 6 NO is synthesized by nitric oxide synthase (NOS), an enzyme which has Excessive consumption of sugar is a public concern and is one of the risk factors that contribute to the development of obesity, diabetes, and related chronic disease. 13 Recently, new low-calorie added sugars have been developed to manage these metabolic diseases. Turanose (3-O--D-glucosyl-D-fructose) is a sucrose isomer that naturally exists in honey and provides one-half of the sweetness provided by sucrose. 14 Turanose is a byproduct of the synthetic reaction of linear -(1,4)-glucan from sucrose, and this reaction can be catalyzed by a recombinant form of an amylosucrase that was originally identified in Neisseria polysaccharea. 15 The hydrolysis rate of turanose has been reported to result in 54% sucrose and 6% maltose at a 5 mM concentration in a rat intestinal enzyme mixture. 16 Turanose is more slowly hydrolyzed to glucose and fructose in the intestine compared with sucrose, and this represents the potential for turanose to serve as a low glycemic alternative sweetener. 17 Support for turanose as a sweetener substitute for sucrose and for the control adipogenesis have also been demonstrated in vitro. 18 We hypothesize that turanose as a representative alternative sweetener can substitute for sucrose and mediates beneficial effects for the management of chronic metabolic diseases. However, few studies have investigated the functional roles of turanose in inflammation. Therefore, the objective of this study was to demonstrate the anti-inflammatory effects of turanose in murine macrophage cells and the potential of this sucrose isomer to serve as functional alternative sweetener for sugar.
MATERIALS AND METHODS

Materials
Turanose (3-O--D-glucosyl-D-fructose; CAS No. 547-25-1) was purchased from Carbosynth Limited (Berkshire, UK) (Fig. 1) . FBS, penicillin, and streptomycin were purchased from Invitrogen (Carlsbad, CA, USA). Dulbecco's Modified Eagle's Medium (DMEM) was purchased from WelGene (Daegu, Korea), MTT, LPS, and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Cell Culture
The mouse macrophage cell line, Raw 264.7 (American Type Culture Collection, Rockville, MD, USA), was cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin (100 U/mL and 100 g/mL). Cells were maintained in 5% CO2 at 37 o C. Raw 264.7 cells were seeded in 6-well culture plates. After 24 hours, the cells were activated with 50 ng/mL LPS (Escherichia coli O111:B4) and treated with a total 25 mM concentration of glucose and turanose in various proportions in cell media for 24 hours. These proportion included: 100% glucose (Glu), 50% Glu/50% turanose (T50), 25% Glu/75% turanose (T75), and 100% turanose (T100).
Cell viability assay
Cell viability was assessed by using a colorimetric MTT assay. 19 Briefly, Raw 264.7 macrophages were seeded in 96-well plates and treated with various proportion of glucose (Glu) and turanose (T50, T75, and T100) as indicated above. After 24 hours, the cells were washed with PBS and incubated with a 0.5 mg/mL MTT stock solution. After 4 hours, the supernatants were aspirated and DMSO was added to dissolve the formazan crystals present in each well. Absorbance values were then measured with a microplate reader (Molecular Devices, Sunnyvale, CA, USA) at 560 nm. The results are expressed as a percentage of the absorbance value for the control group which was set to 100%. Relative NO production levels in the cell culture media treated with 50 ng/mL lipopolysaccharide (LPS) and turanose for 24 hours were examined using Griess reagent. For a given column, data not sharing a common superscript letter significantly differ (P ＜ 0.05). Ctrl, no glucose; Glu, 25 mM glucose; T50, T75, and T100, replaced glucose with the indicated proportion of turanose (e.g., 50%, 75%, or 100%, respectively).
Nitric oxide production assay
The LPS-stimulated inflammatory response in the Raw 264.7 cells was assessed by measuring NO production present in cell culture media as previously described. 10 Briefly, cells were seeded in 96-well plates and activated by 50 ng/mL LPS. After 24 hours, NO levels were measured in the cell culture media supernatants with Griess reagent (1% sulfanilamide, 0.1% N-1-naphthylethylenediamine dihydrochloride, and 5% H3PO4 solution). The media supernatants were transferred to new 96-well plates and mixed with Greiss reagent. After an incubation in the dark for 15 minutes, the absorbance values at 540 nm were measured with a microplate reader (Molecular Devices). The results are expressed as the percentage of absorbance values relative to the control group which was set to 100% NO production.
Quantitative real-time PCR analysis
Total RNA was isolated from Raw 264.7 cells using TRIzol reagent (Invitrogen), and cDNA was prepared by reverse transcription with a RevertAid First Strand cDNA Synthesis Kit (Fermentas, Vilnius, Lithuania). To analyze mRNA levels, quantitative PCR was performed for each gene by using a Rotor-Gene SYBR Green PCR kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Real-time PCR was performed by using a Rotor-Gene Q instrument (Qiagen, Austin, TX, USA) that was programmed as follows: 
Western blot analysis
Western blot analysis was performed as described previously. 
Statistical analysis
Data are presented as the mean ± SEM. All data were analyzed by using GraphPad Prism (GraphPad Software, Inc., San Diego, CA, USA). Data were analyzed with ANOVA followed by the post-hoc The expression levels of -tubulin were used as a loading control. For a given column, data not sharing a common superscript letter significantly differ (P ＜ 0.05). Ctrl, no glucose; Glu, 25 mM glucose; T50, T75, and T100, replaced glucose with the indicated proportion of turanose (e.g., 50%, 75%, or 100%, respectively).
Tukey's honestly significant difference (HSD) test for multiple comparisons. Statistical differences with a P-value less than 0.05 were considered significant.
RESULTS
Effect of turanose on cell viability
Raw 264.7 macrophages were treated with Glu, T50, T75, and T100 for 24 hours before being subjected to MTT assay ( Fig. 2A) . Cell viability was significantly increased in all of the treated groups compared to the non-treated control group. There was no significant differences in viability between the Glu group and any of the turanose treated groups.
Effect of turanose on production of nitric oxide
In the presence of 25 mM glucose, up to a 3.4-fold increase in NO production was observed (P ＜ 0.001). In contrast, treatment with turanose significantly suppressed NO production by 30% and 42% (T75 and T100, respectively) (all P ＜ 0.001) (Fig. 2B) .
Effect of turanose on inflammation and related oxidative stress
Expression levels of the pro-inflammatory enzymes, iNOS and COX-2, were analyzed to investigate the roles that turanose may have in mediating inflammation (Fig. 3) . The levels of both enzymes were significantly up-regulated in the Glu group compared to the untreated control group. Conversely, both was used as a loading control. For a given column, data not sharing a common superscript letter significantly differ (P ＜ 0.05). Ctrl, no glucose; Glu, 25 mM glucose; T50, T75, and T100, replaced glucose with the indicated proportion of turanose (e.g., 50%, 75%, or 100%, respectively). enzyme levels were down-regulated by turanose treatment compared to the Glu group (Fig. 3A, 3Ba, and 3Bb) . In particular, the levels of iNOS expression significantly decreased by 51% and 75% in the T75 and T100 groups, respectively, compared to the Glu group (P ＜ 0.05 and P ＜ 0.001, respectively). COX-2 protein expression was down-regulated in the T50, T75, and T100 groups by 35%, 62%, and 75% (P ＜ 0.05, P ＜ 0.001, and P ＜ 0.001, respectively) compared to the Glu Group. In addition, expression of the antioxidant enzyme, SOD2, increased in the Glu group by approximately 6-fold compared to the control group. The level of SOD2 was down-regulated in the T75 and T100 groups by 78% and 84%, respectively, compared to the Glu group (P ＜ 0.05 and P ＜ 0.01, respectively). These expression levels of SOD2 in the T75 and T100 groups were found to recover to control levels (Fig. 3Bc ).
Effect of turanose on mRNA level of interleukin-1 and interleukin-18
Following induction of an inflammatory response in Raw 264.7 cells treated with LPS, quantitative real-time-PCR was performed to detect mRNA levels of IL-1 and IL-18 (Fig. 4) . Both genes were up-regulated by approximately 7-fold in the Glu group compared to the control group. In contrast, the mRNA levels of IL-1 were decreased by 63%, 73%, and 91% in the T50, T75, and T100 groups, respectively, compared to the Glu group (P < 0.01, P < 0.01, and P < 0.001, respectively) (Fig. 4A) . The mRNA expression levels of IL-18 were down-regulated by 61%, 78%, and 87% in the T50, T75, and T100 groups, respectively, compared to the Glu group (all P ＜ 0.001) (Fig. 4B) . Moreover, in the T100 group, the mRNA levels of IL-1 and IL-18 nearly recovered to each control level.
DISCUSSION
The present study demonstrates that turanose is able to suppress LPS-and glucose-induced inflammatory responses in Raw 264.7 macrophages. Specifically, NO production, expression of pro-inflammatory mediators, including iNOS and COX-2, and expression of the related antioxidant enzyme, SOD2, were significantly decreased in the presence of turanose. In addition, mRNA levels of the immune cytokines, IL-1 and IL-18, were suppressed by turanose.
LPS has previously been applied to Raw 264.7 cells at a concentration of 1 g/mL. 10 Huang et al. 20 activated Raw 264.7 cells with relatively low concentration of LPS (200 ng/mL) and a dramatic increase in NO production was observed. In the present study, the treatment of Raw 264.7 cells with 50 ng/mL LPS for 24 hours significantly increased NO production in the Glu group but decreased in the T75 and T100 groups. These results demonstrate that substitution of glucose for turanose can potentially inhibit the excessive inflammatory response that is induced by both LPS and glucose. When Raw 264.7 cells were treated with turanose, relative protein levels of iNOS, COX-2, and SOD2 were down-regulated. It has been demonstrated that the iNOS and COX-2 represent pro-inflammatory mediators and play critical roles in regulating inflammation. 9, 10 Moreover, SOD2 has been shown to protect cells from oxidative damage by inhibiting the activities of superoxide free radicals (O2 −   ) . 11 The observed down-regulation of SOD2 expression in the present study indicates that lower level of O2 − was achieved, and this is potentially a beneficial effect against inflammatory diseases. Peroxynitrite (ONOO − ) is produced from the reaction between O2 − and NO. Due to the strong reactive property of ONOO − , this substance causes oxidative damage to various biomolecules. Consequently, an increase in NO production has the potential to increase the amount of oxidative damage mediated by ONOO − , while an increase in SOD2 expression could enhance elimination of O2 − from the body. Thus, in the present study, the observed decrease in SOD2 expression following treatment with turanose might be interpreted as a reduction in the inflammatory response, which would be consistent with the observed decrease in NO production.
It is possible that anti-inflammatory mechanisms are specifically related to IL-1 and IL-18. For example, activated IL-1 plays a key role in acute inflammation by respiratory infections and the clearing pathogen, while prolonged activation of IL-1 can leads to chronic systemic inflammation.
12 IL-18 is a converted biologically active form from its inactive precursor form (pro-IL-18). 21 However, to date, activation of IL-18 has only been observed in dendritic cells and macrophages. 6 In the present study, turanose treatment specifically down-regulated mRNA levels of IL-1 and IL-18, which appears to indicate the anti-inflammatory effects of this sugar substitute. Recently, it was reported that stevioside, a diterpene glycoside isolated from Stevia rebaudiana, exhibited an anti-inflammatory effect by suppressing the secretion of pro-inflammatory cytokines, including IL-1, TNF-, and IL-6. 22 In addition, supplementation with xylobiose, a dimer of xylose, down-regulated mRNA expression of IL-1, TNF-, and MCP-1 in db/db mice. 23 As a significant and efficient energy source, sucrose is the most commonly used sweetener and rapidly raises blood glucose after intake. However, excessive consumption of sucrose is associated with metabolic diseases, such as obesity and type 2 diabetes. Therefore, various functional alternative sugar substitutes, including D-xylose, D-tagatose, and isomaltulose, have been developed and investigated for their potential to replace sucrose. [24] [25] [26] [27] For example, a disaccharide made from sucrose, isomaltulose is a well-known sugar replacement which exhibits low-glycemic properties by raising blood glucose and insulin levels at a slower rate than sucrose following its oral administration. 27 A well-controlled blood glucose level is considered to be beneficial for the treatment of an excessive inflammatory response. In addition, an immune-modulating diet containing isomaltulose was shown to suppress a systemic inflammation response following gut ischemia-reperfusion injury in mice. 28 Taken together, these anti-inflammatory effects of isomaltulose are consistent with the results observed in the present study for the sucrose isomer, turanose. Only few studies have reported the hydrolysis rate of turanose using microorganisms, and these studies were limited to in vitro. Hydrolysis of turanose by rat intestinal enzymes was also reported, with a 54% rate achieved for sucrose at a 5 mM concentration level. 29 However, in vivo studies are required to more fully characterize the absorption rate and metabolism of turanose. The absorption and metabolism of another sucrose isomer, isomaltulose, have been characterized with carbohydrate load tests and [
14 C] isomaltulose-radioisotope labeling tests in rats and humans, respectively. No significant differences were observed between the isomaltulose-treated group and the sucrose-treated group. 30 Further studies to investigate the clinical implications of turanose administration are required to explore the potential applications of this molecule as a sugar substitute for humans. The treatment of Raw 264.7 macrophages with turanose resulted in anti-inflammatory effects regulating NO production, inflammatory mediators, and cytokines. Further studies regarding the signaling pathways that mediate these anti-inflammatory effects are needed. These results demonstrate the potential of this sucrose isomer as a dietary supplement for the prevention of metabolic diseases.
